Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS	3	JAN 25	Annual Reload of MEDLINE database
NEWS	4	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS	5	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS	6	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS	7	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS	8	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses
NEWS	9	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS	10	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS	11	APR 02	DWPI: New display format ALLSTR available
NEWS	12	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS	13	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS	14	APR 07	CA/CAplus CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields
NEWS	15	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAplus
NEWS	16	APR 07	MEDLINE Coverage Is Extended Back to 1947

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:56:15 ON 28 APR 2010

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 15:56:52 ON 28 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2010 HIGHEST RN 1220389-58-1
DICTIONARY FILE UPDATES: 26 APR 2010 HIGHEST RN 1220389-58-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10591884.str





chain nodes :
11 12
ring nodes :
1 2 3 4 5 6 7 8 9 10
ring bonds :
1-2 1-6 2-3 2-12 3-4 3-11 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
1-2 1-6 2-3 2-12 3-4 3-11 4-5 5-6 5-7 6-10 7-8 8-9 9-10

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 15:57:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 100686 TO ITERATE

2.0% PROCESSED 2000 ITERATIONS 16 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1994848 TO 2032592
PROJECTED ANSWERS: 14407 TO 17811

L2 16 SEA SSS SAM L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 2.45 2.67

FILE 'CAPLUS' ENTERED AT 15:59:55 ON 28 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Apr 2010 VOL 152 ISS 18
FILE LAST UPDATED: 27 Apr 2010 (20100427/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l2
L3 18 L2

=> d abs fbib 15-18

L3 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
AB In order to obtain antitumor agents, various 7H-pyridocarbazole dimers were prepared by quaternization of the pyridinic N atoms of the different isomeric 7H-pyridocarbazole rings with haloamino alicyclic or aliphatic chains. The dimers interact with DNA more markedly than the corresponding monomers, and the bisintercalation depends upon the nature, flexibility and ionization state of the linking chains. They most often bisintercalate at pH 5, where the chain is protonated, and monointercalate at pH 7.4. The apparent binding consts. (Kap) were 108-109 M-1 at pH 5 and (5 + 105)-(2 + 107) M-1 at pH 7.4. The bisintercalating dimers covered 4 DNA base pairs, whereas most of the monointercalating dimers covered 2 bases pairs. The antitumor activity against L1210 murine leukemia is strongly dependent on the position of attachment and the nature and rigidity of the linking chain. Three highly active dimers were obtained among 7H-pyrido[4,3-c]carbazole dimers with rigid bis(thylpiperidinyl) chains. On the other hand, 2 ellipticine dimers were prepared which were completely inactive against L1210.
AN 1980:604501 CAPLUS Full-text
DN 93:204501
OREF 93:32629a
TI DNA intercalating compounds as potential antitumor agents. 2. Preparation and properties of 7H-pyridocarbazole dimers
AU Pelaprat, Didier; Delbarre, Alain; Guen, Irene Le; Le Pecq, Jean Bernard; Roques, Bernard P.
CS Dep. Chim. Org., Unites Enseign. Rech. Sci. Pharm. Biol., Paris, 75006, Fr.
SO Journal of Medicinal Chemistry (1980), 23(12), 1336-43
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OSC.G 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)

L3 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN

AB Structural studies on the six alkaloids isolated from T. crebriflora are described. Spectral data indicate that five of these alkaloids (A–E) posses the dibenzo[f,h]pyrrolo[1,2-b]isoquinoline skeleton present in tylocrebine. They differ in the number, nature, and distribution of the O-bearing substituents and in the presence or absence of a benzylic-type hydroxyl.
AN 1971:13314 CAPLUS Full-text
DN 74:13314
OREF 74:2149a,2152a
TI Alkaloids of Tylophora. II. Structural studies
AU Rao, Koppaka Visweswara
CS John L. Smith Mem. Cancer Res., Chas. Pfizer and Co., Inc., Maywood, NJ, USA
SO Journal of Pharmaceutical Sciences (1970), 59(11), 1608-11
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English
OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L3 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
AB Irradiation of solns. of thebainequinone (I)or thebainehydroquinone (II) in dioxane under N, using a high-pressure Hg lamp, gave photothebainehydroquinone (III), m. 156–7°. The mechanism was believed to involve intramol. sensitization of the C7–C8 double bond in I and II by the enedione or the hydroquinone system. The photochem. interconversion of I and II was suggested by the observation that each could give III.
AN 1965:51868 CAPLUS Full-text
DN 62:51868
OREF 62:9185b-d
TI Isolation and structure of photothebainehydroquinone
AU Barneis, Z. J.; Wheeler, D. M. S.; Kinstle, T. H.
CS Univ. of Nebraska, Lincoln
SO Tetrahedron Letters (1965), (4), 275-80
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English

L3 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
AB Vat dyes or intermediates are prepd. by the treatment with alk. condensing agents of Bz-2-, -3-, -4-, -6- or -7-azabenzanthrones or homologs or derivs. thereof that are not substituted in either of the peri-positions or are only substituted therein by substituents that are readily split off or that may be connected in a peri-position with an aromatic radical containing at least 2 condensed rings by means of a N bridge. Starting materials having 2 reactive peri-positions (materials wherein 1 peri-position contains a substituent that is easily displaced being included) yield by the above treatment carried out below 100° diazabenzanthronyls but by treatment at higher temps., when a peri-position is occupied by a pyrazolanthrone or anthraquinone or other vattable radical, condensation products containing an acridine ring are obtained. Bz-2-Azabenzanthrones are obtained by condensing anthraquinone-1-carboxylic acid chloride (I) with aminoacetic acid esters, treating the resulting compound with alc., saponifying the resulting ester and splitting off CO2. Bz-3-azabenzanthrones are prepared by treating 4-benzoylisoquinolines having a reactive 5-position with a condensing agent of the AlCl3 type. Bz-4-Azabenzanthrones are similarly derived from 1-benzoylisoquinolines having a reactive 8-position. Bz-6- and Bz-7-azabenzanthrones are obtained from β-anthraquinones or the corresponding reduction products by treatment with glycerol in the presence of H2SO4. Among examples, (1) the azabenzanthrone obtained by treating 2-azanthraquinone with glycerol and H2SO4is condensed with alc. KOH at 140–145°; the product dyes vegetable fibers violet shades, (2) Bz-1-hydroxy-Bz-2-azabenzanthrone, prepared by condensing I with

aminoacetic acid Et ester, splitting off H2O, saponifying and decarboxylating, is treated with KOH at 215-222°; the product dyes blue-green shades, (3) the condensation products of Bz-1-bromodimethyl-6-azabenzanthrone and 1-aminoanthraquinone (II) or pyrazolanthrone or the condensation product of a dibrominated derivative of dimethylazabenzanthrone and II are condensed with alc. KOH at about 140° (olive-green, blue and gray shades, resp.).

AN 1936:65004 CAPLUS Full-text
DN 30:65004
OREF 30:8638b-g
TI Vat dyes; intermediates
PA I. G. Farbenindustrie A.-G.
SO Addn. to 421,264 (C. A. 29, 3531.3)
DT Patent
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 450244		19360710	GB 1934-35445	19341210

=> file registry
COST IN U.S. DOLLARS SINCE FILE TOTAL

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10591884.str



chain nodes :
15
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14
chain bonds :
5-15
ring bonds :
1-2 1-6 2-3 2-14 3-4 3-12 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 13-14
exact/norm bonds :
1-2 1-6 2-3 2-14 3-4 3-12 4-5 5-6 5-7 5-15 6-10 7-8 8-9 9-10 12-13
13-14

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 16:02:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 6746 TO ITERATE

 29.6% PROCESSED 2000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH **COMPLETE**
PROJECTED ITERATIONS: 129995 TO 139845
PROJECTED ANSWERS: 12 TO 392

L5 3 SEA SSS SAM L4

=> s l4 ful
FULL SEARCH INITIATED 16:02:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 132774 TO ITERATE

100.0% PROCESSED 132774 ITERATIONS 215 ANSWERS
SEARCH TIME: 00.00.04

L6 215 SEA SSS FUL L4

=> file caplus

Copyright of the articles to which records in this database refer is

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate

substance identification.

```
=> s l6
L7          15 L6

=> d abs fbib hitstr 10-15
```

L7 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN

AB Oxymorphazole (17-methyl-6,7-dehydro-3,14-dihydroxy-4,5α-epoxy- 6,7:3',4'-pyrazolomorphinan), a hydrophilic opioid, given intracerebroventricularly (2.5-50 nmol) or intrathecally (0.3-5 nmol) dose-dependently produced tail-flick inhibition in male CD-1 mice. However, oxymorphazole given s.c. even at high doses (10-80 mg/kg) produced weak tail-flick inhibition. Oxymorphazole given i.p. (0.1 to 10 mg/kg) dose-dependently inhibited abdominal constriction response induced by i.p. injection of 0.6% acetic acid. Oxymorphazole given intracerebroventricularly (25 nmol) or intrathecally (5 nmol) induced tail-flick inhibition was blocked by pretreatment with the μ-opioid receptor antagonist D-Phe-Cys-Tyr-D-Orn-Thr-Pen-Thr-NH2, but not κ-opioid receptor antagonist nor-binaltorphimine. The δ-opioid receptor antagonist, naltrindole, blocked the tail-flick inhibition induced by oxymorphazole given intrathecally but not intracerebroventricularly. The inhibition of the abdominal constriction response by oxymorphazole given i.p. was blocked by i.p. pretreatment with naloxone, but not naltrindole or nor-binaltorphimine. Thus, oxymorphazole given systemically produces antinociception only with the abdominal constriction test, but not the tail-flick test, suggesting that it produces the antinociception at the peripheral sites when administered systemically. The oxymorphazole-induced antinociception is mainly mediated by the stimulation of μ-opioid receptors when given either centrally or systemically and also the δ-opioid receptors when given intrathecally. The lack of central antinociceptive effect of oxymorphazole given systemically may have interesting clin. implications.

AN 2003:581379 CAPLUS Full-text
DN 140:87492
TI Antinociceptive properties of oxymorphazole in the mouse
AU Wu, Hsiang-en; Sun, Han-Sen; Darpolar, Moses; Dunn, William; Tseng, Leon F.
CS Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA
SO European Journal of Pharmacology (2003), 473(2-3), 143-148
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
IT 644996-43-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antinociceptive properties of oxymorphazole in the mouse)
RN 644996-43-0 CAPLUS
CN 5,10c-(Iminoethano)-10cH-furo[2',3',4',5':4,5]phenanthro[3,2-c]pyrazole-1,5a(6H)-diol, 4,5,9,9b-tetrahydro-13-methyl-, dihydrochloride, (5R,5aS,9bR,10cS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I

AB In an effort to establish the importance of the N-(2-methylallyl) substituent in the noroxymorphone series, several derivs., e.g. I, were synthesized, retaining that N-substituent and modifying the δ address moiety. A few compds. showed moderate binding affinity and selectivity for the δ receptor; none displayed a pharmacol. profile as exceptional as N-(2-methylallyl)noroxymorphindole. A second study showed that 3-O-methylation of all derivs. decreases binding affinity. The present results indicate that only a combination of the N-(2-methylallyl) group and an indole δ address provided high selectivity for the δ receptor.

AN 2001:746618 CAPLUS Full-text
DN 136:69989

TI Derivatives of 17-(2-methylallyl)-substituted noroxymorphone: variation of the delta address and its effects on affinity and selectivity for the delta opioid receptor

AU Ullrich, T.; Dersch, C. M.; Rothman, R. B.; Jacobson, A. E.; Rice, K. C.
CS Laboratory of Medicinal Chemistry, NIDDK, National Institutes of Health, Bethesda, MD, 20892, USA

SO Bioorganic & Medicinal Chemistry Letters (2001), 11(21), 2883-2885
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 136:69989

IT 384820-59-1P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 17-(2-methylallyl)-substituted noroxymorphone derivs. variation of delta address and effects on affinity and selectivity for delta opioid receptor)
RN 384820-59-1 CAPLUS
CN 5,10c-(Iminoethano)-10cH-furo[2',3',4',5':4,5]phenanthro[3,2-c]pyrazol-5a(6H)-ol, 4,5,9,9b-tetrahydro-1-methoxy-13-(2-methyl-2-propenyl)-, (5R,5aS,9bR,10cS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 384820-63-7P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 17-(2-methylallyl)-substituted noroxymorphone derivs. variation of delta address and effects on affinity and selectivity for delta opioid receptor)
RN 384820-63-7 CAPLUS
CN 5,10c-(Iminoethano)-10cH-furo[2',3',4',5':4,5]phenanthro[3,2-c]pyrazole-1,5a(6H)-diol, 4,5,9,9b-tetrahydro-13-(2-methyl-2-propenyl)-, (5R,5aS,9bR,10cS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I II

AB The compds. I and II [R1 = H, C1-6-alkyl, C2-6-alkenyl, C1-3-alkylenearyl, C3-8-cycloalkyl, C1-3-alkylene-C3-8-cycloalkyl, C1-3-alkylene-C3-8-heterocycloalkyl, C3-8-heterocycloalkyl, aryl, aryl-C1-3-alkyl; R2 = halo, CF3, C1-6-alkyl, C3-8-cycloalkyl, C(:O)ORa, ORa, C1-3-alkylene-C3-8-cycloalkyl; R3 = H, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl; Ra = H, C1-6-alkyl, C3-8-cycloalkyl, C1-4-alkylene-C(:O)ORb, aryl, aryl-C1-3-alkyl, C1-3-alkenylaryl, Het; Rb = H, C1-6-alkyl, aryl, aryl, aryl-C1-3-alkyl, C1-3-alkenylaryl, Het; Het = 5 to 6 membered heterocycle, saturated, or partially or fully unsatd., containing at least one of O, N, S, optionally substituted with C1-6-alkyl; n = 0 - 2] and their pharmaceutically acceptable salts and hydrates and their use as therapeutic agents is disclosed. Thus, I (R1 = R2 = H, R3 = Me) and II (R1 = R2 = H, R3 = Me) were prepared from oxymorphone via regioselective O-methylation with Me3SiCHN2 in MeOH/MeCN, condensation with Me2NCHO in Me2NCOMe, cyclocondensation with hydrazine hydrate in aqueous MeOH and O-deprotection with BBr3 in CH2Cl2. Compound I or II is an agonist for the μ and δ opioid receptors, and antagonist for the κ opioid receptor, and has high affinity at all three receptors; compound I or II has utility in a variety of therapeutic and research areas where κ opioid receptor antagonism is beneficial, including the treatment of opiate addiction or pain, or in a method of stimulating an immune system of a human. Thus, I (R1 = R2 = H, R3 = Me) and II (R1 = R2 = H, R3 = Me) have high affinity for opioid receptors: Ki (SEM) = 3.75 (0.71) nM vs. μ opioid receptor ([3H]-DAMGO); Ki (SEM) = 19.06 (1.17) vs. δ opioid receptor ([3H]-Cl-DPDPE); Ki (SEM) = 12.29 (6.20) nM vs. κ opioid receptor ([3H]-U69,593).

AN 2001:472723 CAPLUS Full-text

DN 135:61469

TI Preparation of nonpeptide kappa opioid receptor antagonists

IN Dunn, William; Bauer, Ludwig; Bhargava, Hemendra N.

PA Board of Trustees of the University of Illinois, USA

SO PCT Int. Appl., 25 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001046198	A2	20010628	WO 2000-US42464	20001130
WO 2001046198	A3	20020510		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 1999-454670 A 19991203

US 6284769 B1 20010904 US 1999-454670 19991203

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 135:61469; MARPAT 135:61469

IT 259173-73-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of nonpeptide kappa opioid receptor antagonists and mu and delta opioid receptor agonists)

RN 259173-73-4 CAPLUS

CN 5,10c-(Iminoethano)-10cH-furo[2',3',4',5':4,5]phenanthro[3,2-c]pyrazole-1,5a(6H)-diol, 4,5,9,9b-tetrahydro-13-methyl-, (5R,5aS,9bR,10cS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 345238-02-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nonpeptide kappa opioid receptor antagonists and mu and delta opioid receptor agonists)

RN 345238-02-0 CAPLUS

CN 5,10c-(Iminoethano)-10cH-furo[2',3',4',5':4,5]phenanthro[3,2-c]pyrazol-1,5a(6H)-diol, 4,5,9,9b-tetrahydro-13-methyl-, monohydrochloride, (5R,5aS,9bR,10cS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 7096-91-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nonpeptide kappa opioid receptor antagonists and mu and delta opioid receptor agonists)
RN 7096-91-5 CAPLUS
CN 5,10c-(Iminoethano)-10cH-furo[2',3',4',5':4,5]phenanthro[3,2-c]pyrazol-5a(6H)-ol, 4,5,9,9b-tetrahydro-1-methoxy-13-methyl-, (5R,5aS,9bR,10cS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I

AB A class of opioid receptor-active derivs. of naltrexone has been synthesized using a common enaminone intermediate. The intermediate used in the synthesis is prepared from DMF di-Me acetal and naltrexone and can be isolated and characterized. The derivs. [I; R = H, Me, Ph, NH2] have heterocyclic groups fused to the 6,7-positions of the morphinan system and all were synthesized in 82-100% yield. All compds. were very high affinity, nonselective antagonists for the opioid receptors.

AN 2000:27207 CAPLUS Full-text

DN 132:194534

TI Synthesis and opioid receptor binding properties of 17-cyclopropylmethyl-6,7-dehydro-3,14-dihydroxy-4,5α-epoxy-6,7:4',5' -pyrimidinomorphinans

AU Xu, Wei; Huang, Liang-Fu; Bauer, Ludwig; Bhargava, Hemendra N.; Dunn, William J., III

CS College of Pharmacy, University of Illinois at Chicago, Chicago, IL, 60612-7231, USA

SO Medicinal Chemistry Research (1999), 9(6), 389-407
CODEN: MCREEB; ISSN: 1054-2523

PB Birkhaeuser Boston

DT Journal

LA English

OS CASREACT 132:194534

IT 259827-05-9P 259827-11-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and opioid receptor binding properties of 17-cyclopropylmethyl-6,7-dehydro-3,14-dihydroxy-4,5α-epoxy-6,7:4',5' -pyrimidinomorphinans)

RN 259827-05-9 CAPLUS

CN 5,10c-(Iminoethano)-10cH-furo[2',3',4',5':4,5]phenanthro[3,2-c]pyrazole-1,5a(6H)-diol, 13-(cyclopropylmethyl)-4,5,9,9b-tetrahydro-, (5R,5aS,9bR,10cS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259827-11-7 CAPLUS

CN 5,10c-(Iminoethano)-10cH-furo[2',3',4',5':4,5]phenanthro[3,2-c]pyrazole-1,5a(6H)-diol, 13-(cyclopropylmethyl)-4,5,9,9b-tetrahydro-, dihydrochloride, (5R,5aS,9bR,10cS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

IT 259827-18-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and opioid receptor binding properties of 17-cyclopropylmethyl-6,7-dehydro-3,14-dihydroxy-4,5α-epoxy-6,7:4',5' -pyrimidinomorphinans)
RN 259827-18-4 CAPLUS
CN 5,10c-(Iminoethano)-10cH-furo[2',3',4':4,5]phenanthro[3,2-c]pyrazol-5a(6H)-ol, 13-(cyclopropylmethyl)-4,5,9,9b-tetrahydro-1-methoxy-, (5R,5aS,9bR,10cS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
AB A class of opioid receptor active derivs. of oxymorphone was synthesized using a common enaminone intermediate. The derivs. have pyrimidino or pyrazolo rings fused to the 6,7-positions of the morphinan system and all were synthesized in high yield. A pyrazolo derivative is an agonist for the μ and δ receptors and an antagonist for the κ receptor.
AN 1999:810829 CAPLUS Full-text
DN 132:180743
TI Synthesis and opiate receptor binding properties of 17-methyl-6,7-dehydro-3,14-dihydroxy-4,5α-epoxy-6,7:4',5'-

pyrimidinomorphinans

AU Xu, Wei; Huang, Liang-Fu; Bauer, Ludwig; Bhargava, Hemendra N.; Dunn, William J., III

CS College of Pharmacy, University of Illinois at Chicago, Chicago, IL, 60612-7231, USA

SO Bioorganic & Medicinal Chemistry Letters (1999), 9(23), 3375-3380
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

IT 259173-73-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and opiate receptor binding of dehydrohydroxyepoxypyazolomorphinan)

RN 259173-73-4 CAPLUS

CN 5,10c-(Iminoethano)-10cH-furo[2',3',4',5':4,5]phenanthro[3,2-c]pyrazole-1,5a(6H)-diol, 4,5,9,9b-tetrahydro-13-methyl-, (5R,5aS,9bR,10cS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN

GI For diagram(s), see printed CA Issue.

AB A soln. of 12 g. 14-hydroxydihydrocodeinone (I) and 8 g. p-MeC6H4SO3H in 40 ml. McOH was adjusted to pH 2 with p-MeC6H4SO3H, treated with 12 ml. trimethyl orthoformate, refluxed 2 hrs., poured into N NaOH, and filtered. The precipitate was washed with 500 ml. ether to give 14-hydroxy-6-methoxy-Δ6.7-dihydrodeoxycodeine (II), m. 196-7°, [α]D -228°. The ether solution gave 6,6-dimethoxy-14-hydroxydihydrodeoxycodeine (III), m. 121-2°, [α]D-179°. Similarly were prepared 6-ethoxy-14hydroxy-Δ6.7-dihydrodeoxycodeine, m. 182-4°, [α]D -231°, and 6-butoxy-14-hydroxy-Δ6.7- dihydrodeoxycodeine, m. 121-2°, [α]D -228°. Enol ethers of higher alcs. were slightly more difficult to prepare A mixture of 1 g. I, 0.66 g. p-MeC6H4SO3H, 5 ml. tricyclohexyl orthoformate, and a trace of cyclohexanol was heated under reflux in toluene 4 hrs. with azeotropic distillation of H2O to give 65% 6-cyclohexyloxy-14-hydroxy-Δ6.7- dihydrodeoxycodeine, m. 160.5-1.5°, [α]D -220°. Similarly a mixture of 9 g. I, 4 ml. morpholine, and 3 g. p-MeC6H4SO3H in 100 ml. PhMe was heated 2 hrs. with azeotropic distillation of H2O to give 9.2 g. 14-hydroxy-6-

morpholino-Δ6.7 -dihydrodeoxycodeine, m. 201-2°, [α]D -282°. Similarly were prepared 14-hydroxy-6-pyrrolidino-Δ6.7-dihydrodeoxycodeine, m. 190-1°, [α]D -300°, and 14-hydroxy-6-methylanilino-Δ6.7- dihydrodeoxycodeine, m. 195-6°, [α]D -58°. The Vilsmeier reaction was carried out by adding a solution of the alkaloid in 1,2-dichloroethane to the Vilsmeier reagent prepared from POCl3 and dimethylformamide in the same solvent at 0°. The mixture was heated at appropriate temperature and finally hydrolyzed in aqueous solution buffered to the required pH. Thus a mixture of 12 g. II and III in 100 ml. 1,2-dichloroethane and a mixture of 20 ml. dimethylformamide and 12 mh POCl3 in 20 ml. 1,2-dichloroethane was heated at 65-70° 7 hrs., added to 40 g. Na2HPO4 in 1 h H2O, pH adjusted to between 8 and 9.5 with 2N NaOH, and the mixture stirred 30 min. and extracted with CHCl3 to give a product which contained about 20% 6-chloro-7-formyl-14-hydroxy-Δ6.7- dihydrodeoxycodeine (IV). This substance was refluxed in MeOH solution with NaOAc 6 hrs. to give 6.5 g. 7-formyl-14-hydroxy-6-methoxy-Δ6.7- dihydrodeoxycodeine (V), m. 185-6°. The residue from the mother liquors on chromatography over Al2O3 gave 14-chloro-6-methoxy-Δ6.7-dihydrodeoxycodeine, m. 164-5°, [α]D -235°, thebaine, and IV, m. 173-4°, [α]D -307°. However, 6 g. II in a Vilsmeier reaction at 40° and hydrolyzed at pH 9 gave 3.7 g. 14-formyloxy-6-methoxy-Δ6.7-dihydrodeoxycodeine, m. 178-80° (decomposition). Similarly were prepared 6-ethoxy-7-formyl-14-hydroxy-Δ6.7-dihydrodeoxycodeine, m. 220-1°, [α]D -387°, 6-butoxy-7-formyl-15-hydroxy-Δ6.7-dihydrodeoxycodeine, m. 144-4.5°, [α]D -317-4°,
7-formyl-14-hydroxy-6-morpholino-Δ6.7-dihydrodeoxycodeine, m. 174-5°, [α]D -286°, and
7-formyl-14-hydroxy-6-pyrrolidino-Δ6.7-dihydrodeoxycodeine, m. 241-3°, [α]D -567°. Reduction of 7-formyl compds. gave the corresponding primary alcs. which were acetylated. Thus 20 g. V in 100 ml. tetrahydrofuran was reduced with 3 g. LiBH4 to give 85% 14-hydroxy-7-hydroxymethyl-Δ6.7-dihydrodeoxycodeine (VI), m. 164-5, [α]D -251°. Similarly were prepared 6-ethoxy-14-hydroxy-7-hydroxymethyl-Δ6.7-dihydrodeoxycodeine, m. 122-3°, [α]D -246°,
6-chloro-14-hydroxy-7-hydroxymethyl-Δ6.7-dihydrodeoxycodeine, m. 208-9°, and 6-dimethylamino-
14-hydroxy-7-hydroxymethyl-Δ6.7-dihydrodeoxycodeine borane adduct, m. 300° (decomposition). Acetylation of 0.5 g. VI with 0.16 ml. Ac2O and 3 ml. pyridine at room temperature 16 hrs. gave 0.32 g. 7-acetoxymethyl-14-hydroxy-6-methoxy-Δ6.7-dihydrodeoxycodeine, m. 154.5-56°. Other esters of VI prepared were: 7-diethylacetate, m. 91-2°, 7-o-toluate, m. 123-4°, 7-phenyldiethylacetate, m. 128-9°, and 7-propionate, m. 108-9°. Similarly were prepared 7-benzoyloxy-6-ethoxy-14-hydroxy-Δ6.7-dihydrodeoxycodeine, m. 128-8.5°, and 7-furoate, m. 100-1°. Acid hydrolysis of 7-formyl-6-enol ethers was carried out by dissolving 0.15 g. compound in 0.5 ml. concentrated HCl, keeping the mixture at room temperature 15 min., and basifying to pH 9.5 to give amorphous 14-hydroxy-7-hydroxymethylenedihydrocodeinone (VII) which as expected was soluble in alkali and gave a purple color with FeCl3 and a typical spectrum of an enolic β-dicarbonyl compound VII was also obtained by dissolving 0.5 g. 7-formyl-6-enol ether in 1 ml. NaOH, keeping at room temperature for a few min., and acidifying to pH 9.5. A solution of I g. VII in 50 ml. H2O containing slightly more than i equivalent NaOH was stirred with 2 ml. MeI for 48 hrs. at room temperature to give 0.4 g. 14-hydroxy-7-methyldihydrocodeinone, m. 226-8° (decomposition), [α]D -187°, which was also obtained by methylation of I with MeI-NaNH2 in liquid NH3 solution Hydrolysis of 6-dialkylamino-7-formyl-14-hydroxydihydrodeoxycodeine derivs. was carried out by dissolving 0.5 g. compds. in excess 5N HCl, keeping at room temperature, basifying to pH 9.5, and chromatographing the product on AlcOa to

give the starting material, 6-dialkylamino-14 -hydroxy-Δ6.7-dihydrodeoxycodeine and I, m. 218-19. More vigorous treatment with HCl gave only I. When treated with slight excess of EtOH-NaOH for 30 min. the only product was VII. The formyl compds. (V) gave 96% yield of the oxime, 14-hydroxy-7-hydroxyiminomethyl-6- methoxydihydrodeoxycodeine, m. 242-3°, [α]D -216°. Heating 4 g. of the oxime with 25 ml. Ac2O 1 hr. gave 2.9 g. 14-acetoxy-7cyano-6-methoxy-Δ6.7-dihydrodeoxycodeine, m. 176-6.5°, [α]D -305°, which on hydrolysis with 1 equivalent EtOH-NaOH gave 7-cyano-14-hydroxy-6-methoxy-Δ6.7-dihydrodeoxycodeine, m. 233-5°, [α]D -311°. On heating 1 g. oxime with 4 ml. concentrated HCl at 60° for 20 min. was obtained isoxazolyl-[6,7-d]-14-hydroxydihydrodeoxycodeine, m. 189-90°, [α]D -336°. The structure was proposed on the basis of its insolubility in NaOH and its infrared spectrum. The compound V gave 82% yield of semicarbazone, m. 268-70° (decomposition), which (0.5 g.) on heating with dilute HCl at 100° for 2 hrs. gave 0.3 g. pyrazolinyl[6,7-c]-14-hydroxydihydrodeoxycodeine, m. 290° (decomposition). It was also obtained by refluxing 1 g. V and 0.3 g. NH2NH2.HCl in 50 ml. EtOH 2 hrs. and basifying the solution with Na2CO3. The OMe group in V was easily replaced by heating it with ureas. Thus a solution of 1 g. V and 0.33 g. butylurea in 50 ml. EtOH containing 2 ml. HOAc was refluxed 2 hrs. to give 0.9 g. butylureido-7-formyl-14- hydroxy-Δ6.7-dihydrodeoxycodeine, m. 250-2° (decomposition), [α]D -486°. Similarly were prepared 6-tert-butylureido-7-formyl14-hydroxy-Δ6.7-dihydrodeoxycodeine, m. 268°, and 6-(N,N-diethylinreido)-7-formyl-14-hydroxy-Δ6.7- dihydrodeoxycodeine, m. 220°. Since II did not react under these conditions the activating effect of the 7-formyl group was apparent. Reaction of V with PhNH2 yielded 3 distinct products depending on the conditions used. A solution of 1 g. V and 0.26 ml. (equimolar quantity) PhNH2 in a min. volume MeOH was refluxed 30 min. to give 0.78 g. of the normal anil, 14-hydroxy-6-methoxy-7-phenyliminomethyl-Δ6.7-dihydrodeoxycodeine, m. 176-7°. Longer reaction with excess PhNH2 led to replacement of the OMe by the anilino group. Thus a solution of 0.5 g. anil and 0.13 ml. PhNH2 in MeOH was refluxed 16 hrs. to give 0.32 g. 6-anilino-7-formyl-14-hydroxy-Δ6.7-dihydrodeoxycodeine, m. 280° (decomposition). It was also formed by heating 1 g. V with 1 g. aniline sulfate in 100 ml. EtOH 4 hrs. In the presence of acid a quinoline was obtained. Thus, a solution of 0.5 g. anil, 0.13 g. PhNH2, and a trace of aniline hydrochloride in EtOH was refluxed 16 hrs. to give 0.88 g. quinolino [6,7-b]-14-hydroxydihydrodeoxycodeine, m. 280° (decomposition). The anil and p-ClC2H4NH2 similarly gave 6'-chloroquinolino [6,7b]-14-hydroxydihydrodeoxycodeine, m. 285° (decomposition). The anil was recovered by boiling several hrs. in EtOH. The mechanism of formation of quinoline derivs. was discussed in detail. The Vilsmeier reaction of I was next studied. A solution of 12 g. I in 1,2-dichloroethane was added to a solution of 12 ml. POCl3 and 20 ml. HCONMe2 in the same solvent, the mixture heated at 70° 7 hrs., and product hydrolyzed to give 2.4 g. IV, 1.8 g. 6-dimethylamino-7-formyl-14-hydroxy-Δ6.7-dihydrodeoxycodeine (VIII), m. 258° (decomposition), [α]D -2°, and 1.2 g. of a dimeric product (IX), m. 192-3° (decomposition), [α]D -290°. The yields of IV and IX were the same whether hydrolysis was carried out at pH 4-6 or pH 10, but VIII was not isolated when acid hydrolysis was carried out. The yield of IX increased at the expense of IV and VIII if I was added to the reaction mixture immediately before hydrolysis. IV could not be converted into VIII nor could the yield of VIII be improved by adding Me2NH before hydrolysis. The mechanism of reaction of all these reactions was discussed. The structure of IX was demonstrated by its cleavage in acid solution or on fusion to yield equimolar mixture of IV and I, and finally by its synthesis by the action of IV and I in MeOH containing NaOMe at room temperature The ultraviolet and infrared spectra of most of the compds. were given and discussed in detail.

AN 1964:432654 CAPLUS Full-text
DN 61:32654

OREF 61:5705h,5706a-h,5707a-f
TI Vilsmeier reactions with 14-hydroxydihydrocodeinone and derived enol ethers
AU Lester, M. G.; Petrow, V.; Stephenson, O.
CS Brit. Drug Houses Ltd., London
SO Tetrahedron (1964), 20(6), 1407-17
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA Unavailable
OS CASREACT 61:32654
IT 7096-91-5P, 5,10c-(Iminoethano)-10cH-furo[2',3',4',5':4,5]phenanthro[3,2-c]pyrazol-5aβ(6H)-ol, 4,5a,9,9bβ-tetrahydro-1-methoxy-13-methyl-
RL: PREP (Preparation)
(preparation of)
RN 7096-91-5 CAPLUS
CN 5,10c-(Iminoethano)-10cH-furo[2',3',4',5':4,5]phenanthro[3,2-c]pyrazol-5a(6H)-ol, 4,5,9,9b-tetrahydro-1-methoxy-13-methyl-, (5R,5aS,9bR,10cS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

=> d abs fbib hitstr 5-9

L7 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
AB Addn. of the 4-fluorophenylpyrazole group to the previously described 2-azadecalin glucocorticoid receptor (GR) antagonist 1 resulted in significantly enhanced functional activity. SAR of the bridgehead substituent indicated that whereas groups as small as Me afforded high GR binding, GR functional activity was enhanced by larger groups such as benzyl, substituted ethers, and aminoalkyl derivs. GR antagonists with binding and functional activity comparable to mifepristone were discovered (e.g., 52: GR binding Ki 0.7 nM; GR reporter gene functional Ki 0.6 nM) and found to be highly selective over other steroid receptors. Analogs 43 and 45 had >50% oral bioavailability in the dog.
AN 2008:232071 CAPLUS Full-text
DN 148:440269
TI 1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity
AU Clark, Robin D.; Ray, Nicholas C.; Williams, Karen; Blaney, Paul; Ward, Stuart; Crackett, Peter H.; Hurley, Christopher; Dyke, Hazel J.; Clark, David E.; Lockey, Peter; Devos, Rene; Wong, Melanie; Porres, Soraya S.; Bright, Colin P.; Jenkins, Robert E.; Belanoff, Joseph

CS Corcept Therapeutics, Menlo Park, CA, 94025, USA
SO Bioorganic & Medicinal Chemistry Letters (2008), 18(4), 1312-1317
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 148:440269
IT 864972-02-1P 864972-29-2P 864972-39-4P
864972-43-0P 864972-55-4P 1018679-76-9P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(1H-pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists)
RN 864972-02-1 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-29-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(methoxymethyl)-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-39-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-(methoxymethyl)-, (4aR)-(CA INDEX NAME)

Absolute stereochemistry.



RN 864972-43-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(methoxymethyl)-6-(phenylsulfonyl)-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-55-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(4-morpholinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1018679-76-9 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(methoxymethyl)-6-[[4-(trifluoromethyl)phenyl]sulfonyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



IT 864971-93-7P 864972-25-8P 864972-26-9P
864972-28-1P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(1H-pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists)

RN 864971-93-7 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-(phenylmethyl)- (CA INDEX NAME)



RN 864972-25-8 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanol, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-26-9 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanol, 1-(4-fluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-1,4,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-28-1 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanol, 1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-(phenylsulfonyl)-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



IT 864971-84-6P 864972-04-3P 864972-05-4P
864972-09-8P 864972-10-1P 864972-11-2P
864972-12-3P 864972-19-0P 864972-30-5P
864972-32-7P 864972-33-8P 864972-34-9P
864972-36-1P 864972-37-2P 864972-38-3P
864972-40-7P 864972-41-8P 864972-42-9P
864972-54-3P 864972-58-7P 864972-59-8P
864972-60-1P 864972-61-2P 864972-62-3P
864972-63-4P 864972-64-5P 864972-69-0P
864972-70-3P 864972-71-4P 864972-72-5P
864972-75-8P 864972-76-9P 864972-77-0P
864972-78-1P 864972-79-2P 864972-85-0P
864972-27-3P 864973-28-4P 864973-29-5P
864973-30-8P 864973-31-9P 864973-32-0P
864973-36-4P 864973-37-5P 864973-38-6P
864973-39-7P 864973-40-0P 864973-45-5P
864973-47-7P 864973-48-8P 1018679-69-0P
1018679-79-2P 1018679-81-6P 1018679-85-0P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(1H-pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists)
RN 864971-84-6 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(phenylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-04-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-6-[(4-methylphenyl)sulfonyl]-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-05-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-6-[[4-(trifluoromethyl)phenyl]sulfonyl]-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-09-8 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-6-[(4-methoxyphenyl)sulfonyl]-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-10-1 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-11-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-6-[(2-fluorophenyl)sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-12-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-6-[(2-methylphenyl)sulfonyl]-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-19-0 CAPLUS
CN Benzenamine, 4-[[(4aS)-1-(4-fluorophenyl)-1,4,4a,5,7,8-hexahydro-4a-methyl-6H-pyrazolo[3,4-g]isoquinolin-6-yl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-30-5 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[(2-methoxyethoxy)methyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-32-7 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4a-(ethoxymethyl)-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-33-8 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[(3-methoxypropoxy)methyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-34-9 CAPLUS
CN Propanenitrile, 3-[[(4aR)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-36-1 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[[2-(1-piperidinyl)ethoxy]methyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-37-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[[2-(1-pyrrolidinyl)ethoxy]methyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-38-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-[(2-methoxyethoxy)methyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-40-7 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(methoxymethyl)-6-[(4-methylphenyl)sulfonyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-41-8 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[(2-methoxyethoxy)methyl]-6-[(4-methylphenyl)sulfonyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-42-9 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[(2-methoxyethoxy)methyl]-6-(phenylsulfonyl)-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-54-3 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-N,N-dimethyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-58-7 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(1-pyrrolidinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-59-8 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine,
6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-N-ethyl-1-(4-fluorophenyl)-
1,4,5,6,7,8-hexahydro-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-60-1 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine,
6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-N,N-diethyl-1-(4-fluorophenyl)-
1,4,5,6,7,8-hexahydro-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-61-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-
1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(1-piperidinylmethyl)-,
(4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-62-3 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-N-(2-methoxyethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-63-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[(4-methyl-1-piperazinyl)methyl]-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-64-5 CAPLUS
CN 1,2-Ethanediamine, N2-[[(4aS)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]methyl]-N1,N1-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-69-0 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-N-(1-methylethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-70-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 4a-(1-azetidinylmethyl)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-71-4 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-N-2-propen-1-yl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-72-5 CAPLUS
CN Ethanol, 2-[[[(4aS)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]methyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-75-8 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 1-(4-fluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-1,4,5,6,7,8-hexahydro-N,N-dimethyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-76-9 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-(1-pyrrolidinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-77-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-6-(phenylsulfonyl)-4a-(1-pyrrolidinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-78-1 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-N,N-dimethyl-6-(phenylsulfonyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-79-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(4-morpholinylmethyl)-6-(phenylsulfonyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-85-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-6-(phenylsulfonyl)-4a-(1-piperidinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-27-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro- (CA INDEX NAME)



RN 864973-28-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-(phenylsulfonyl)- (CA INDEX NAME)



RN 864973-29-5 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



RN 864973-30-8 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-6-[(4-fluorophenyl)sulfonyl]-4,4a,5,6,7,8-hexahydro- (CA INDEX NAME)



RN 864973-31-9 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-(methylsulfonyl)- (CA INDEX NAME)



RN 864973-32-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-(butylsulfonyl)-1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro- (CA INDEX NAME)



RN 864973-36-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[6-(1,1-dimethylethyl)-3-pyridinyl]sulfonyl]-1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro- (CA INDEX NAME)



RN 864973-37-5 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-[[4-(4-morpholinyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 864973-38-6 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 864973-39-7 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 864973-40-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 864973-45-5 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-phenyl- (CA INDEX NAME)



RN 864973-47-7 CAPLUS
CN 6H-Pyrazolo[3,4-g]isoquinoline-6-sulfonamide, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-1,4,4a,5,7,8-hexahydro-N-phenyl- (CA INDEX NAME)



RN 864973-48-8 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-(4-morpholinylsulfonyl)- (CA INDEX NAME)



RN 1018679-69-0 CAPLUS
CN Methanone, [1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-1,4,4a,5,7,8-hexahydro-6H-pyrazolo[3,4-g]isoquinolin-6-yl]phenyl- (CA INDEX NAME)



RN 1018679-79-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 4a-(ethoxymethyl)-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-6-[[4-(trifluoromethyl)phenyl]sulfonyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1018679-81-6 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(propoxymethyl)-6-[[4-(trifluoromethyl)phenyl]sulfonyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1018679-85-0 CAPLUS
CN Ethanol, 2-[[(4aR)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



IT 864972-01-0P 864972-21-4P 864972-53-2P
1018679-86-1P 1018679-87-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(1H-pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists)
RN 864972-01-0 CAPLUS
CN 6H-Pyrazolo[3,4-g]isoquinoline-6-carboxylic acid, 1-(4-fluorophenyl)-1,4,4a,5,7,8-hexahydro-4a-methyl-, 1,1-dimethylethyl ester, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-21-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline-4a,6(4H,5H)-dicarboxylic acid, 1-(4-fluorophenyl)-7,8-dihydro-, 6-(1,1-dimethylethyl) 4a-methyl ester, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-53-2 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxaldehyde, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1018679-86-1 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxaldehyde, 1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-(phenylsulfonyl)-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1018679-87-2 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxaldehyde, 1-(4-fluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-1,4,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I



II

AB Title compds. I [L1 and L2 independently = a bond, O, S, etc.; A = (un)substituted 5-6 membered heterocycloalkyl or heteroaryl; R1 = H, (un)substituted alkyl, heteroalkyl, etc.; R2 = (un)substituted alkyl, heteroalkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of glucocorticoid receptor. Thus, II was prepared by cyclization of (S)-8a-benzyl-2-(4-tert-butyl-benzenesulfonyl)-7-[1-hydroxy-meth-(Z)- ylidene]-1,3,4,7,8,8a-hexahydro-2H-isoquinolin-6-one (preparation given) with hydrazine hydrate. The activity of I was evaluated in glucocorticoid receptor binding assay and it was revealed that selected compds. of the invention displayed IC50 values in the range of 10 up to 100 nm and others below 10 nM. Pharmaceutical compns. comprising I are disclosed.

AN 2005:1021750 CAPLUS Full-text

DN 143:306309

TI Preparation of triazacyclopenta[b]naphthalene derivatives as modulators of glucocorticoid receptor

IN Clark, Robin D.; Ray, Nicholas C.; Blaney, Paul M.; Hurley, Christopher A.; Williams, Karen

PA Corcept Therapeutics, Inc., USA

SO PCT Int. Appl., 160 pp.
CODEN: PIXXD2

DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005087769	A1	20050922	WO 2005-US8049	20050309
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2004-551836P	P 20040309
	AU 2005222421	A1	20050922	AU 2005-222421	20050309
				US 2004-551836P	P 20040309
				WO 2005-US8049	W 20050309
	CA 2558899	A1	20050922	CA 2005-2558899	20050309
				US 2004-551836P	P 20040309
				WO 2005-US8049	W 20050309
	EP 1735308	A1	20061227	EP 2005-725295	20050309
	EP 1735308	B1	20080910		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
				US 2004-551836P	P 20040309
				WO 2005-US8049	W 20050309
	CN 101027301	A	20070829	CN 2005-80011481	20050309
				US 2004-551836P	P 20040309
				WO 2005-US8049	W 20050309
	JP 2007528417	T	20071011	JP 2007-503030	20050309
				US 2004-551836P	P 20040309
				WO 2005-US8049	W 20050309
	AT 407934	T	20080915	AT 2005-725295	20050309
				US 2004-551836P	P 20040309
	PT 1735308	E	20081202	PT 2005-725295	20050309
				US 2004-551836P	P 20040309
	ES 2313317	T3	20090301	ES 2005-725295	20050309
				US 2004-551836P	P 20040309
	ZA 2006008306	A	20090225	ZA 2006-8306	20061005
				US 2004-551836P	P 20040309
	KR 2007029684	A	20070314	KR 2006-720988	20061009
				US 2004-551836P	P 20040309
				WO 2005-US8049	W 20050309
	IN 2006CN03745	A	20070615	IN 2006-CN3745	20061009
				US 2004-551836P	P 20040309
				WO 2005-US8049	W 20050309
	US 20070281928	A1	20071206	US 2007-591884	20070507
				US 2004-551836P	P 20040309
				WO 2005-US8049	W 20050309
	HK 1104813	A1	20090403	HK 2007-106903	20070627
				US 2004-551836P	P 20040309
				WO 2005-US8049	W 20050309

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 143:306309; MARPAT 143:306309
IT 864972-21-4P 864972-32-5P 864972-53-2P
864972-96-3P 864972-98-5P 864973-03-5P
864973-18-2P 864973-19-3P 864973-20-6P

864973-21-7P 864973-22-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of triazacyclopenta[b]naphthalene derivs. as modulators of glucocorticoid receptor)

RN 864972-21-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline-4a,6(4H,5H)-dicarboxylic acid, 1-(4-fluorophenyl)-7,8-dihydro-, 6-(1,1-dimethylethyl) 4a-methyl ester, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-22-5 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxylic acid, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, methyl ester, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-53-2 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxaldehyde, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-96-3 CAPLUS

CN 1H-Pyrazolo[3,4-g]isoquinoline-4a,6(4H,5H)-dicarboxylic acid, 1-(4-fluorophenyl)-7,8,8a,9-tetrahydro-, 6-(1,1-dimethylethyl) 4a-methyl ester, (4aR,8aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-98-5 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanol, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8,8a,9-octahydro-, (4aR,8aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-03-5 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxylic acid, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-18-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4a-(1,3-dithian-2-ylidenemethyl)-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-19-3 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-acetic acid, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, methyl ester, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-20-6 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-ethanol, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-21-7 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(2-methoxyethyl)-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-22-8 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-acetaldehyde, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



IT	864971-79-9P	864971-80-2P	864971-81-3P
	864971-83-5P	864971-84-6P	864971-85-7P
	864971-86-8P	864971-87-9P	864971-88-0P
	864971-89-1P	864971-90-4P	864971-91-5P
	864971-92-6P	864971-93-7P	864971-94-8P
	864971-97-1P	864971-98-2P	864972-01-0P
	864972-02-1P	864972-03-2P	864972-04-3P
	864972-05-4P	864972-06-5P	864972-07-6P
	864972-08-7P	864972-09-8P	864972-10-1P
	864972-11-2P	864972-12-3P	864972-13-4P
	864972-14-5P	864972-15-6P	864972-16-7P
	864972-17-8P	864972-18-9P	864972-19-0P
	864972-20-3P	864972-23-6P	864972-24-7P
	864972-25-8P	864972-26-9P	864972-27-0P
	864972-28-1P	864972-29-2P	864972-30-5P
	864972-31-6P	864972-32-7P	864972-33-8P
	864972-34-9P	864972-35-0P	864972-36-1P
	864972-37-2P	864972-38-3P	864972-39-4P
	864972-40-7P	864972-41-8P	864972-42-9P
	864972-43-0P	864972-44-1P	864972-45-2P
	864972-46-3P	864972-47-4P	864972-48-5P
	864972-49-6P	864972-50-9P	864972-51-0P
	864972-52-1P	864972-54-3P	864972-55-4P
	864972-56-5P	864972-57-6P	864972-58-7P
	864972-59-8P	864972-60-1P	864972-61-2P
	864972-62-3P	864972-63-4P	864972-64-5P
	864972-65-6P	864972-66-7P	864972-67-8P
	864972-68-9P	864972-69-0P	864972-70-3P
	864972-71-4P	864972-72-5P	864972-73-6P
	864972-74-7P	864972-75-8P	864972-76-9P
	864972-77-0P	864972-78-1P	864972-79-2P
	864972-80-5P	864972-81-6P	864972-82-7P

864972-83-8P	864972-84-9P	864972-85-0P
864972-86-1P	864972-87-2P	864972-88-3P
864972-89-4P	864972-90-7P	864972-91-8P
864972-92-9P	864972-93-0P	864972-94-1P
864972-95-2P	864972-97-4P	864972-99-6P
864973-00-2P	864973-01-3P	864973-02-4P
864973-04-6P	864973-05-7P	864973-06-8P
864973-08-0P	864973-09-1P	864973-11-5P
864973-12-6P	864973-13-7P	864973-14-8P
864973-15-9P	864973-16-0P	864973-17-1P
864973-23-9P	864973-24-0P	864973-25-1P
864973-26-2P	864973-27-3P	864973-28-4P
864973-29-5P	864973-30-8P	864973-31-9P
864973-32-0P	864973-33-1P	864973-34-2P
864973-35-3P	864973-36-4P	864973-37-5P
864973-38-6P	864973-39-7P	864973-40-0P
864973-41-1P	864973-42-2P	864973-43-3P
864973-44-4P	864973-45-5P	864973-46-6P
864973-47-7P	864973-48-8P	864973-49-9P
864973-50-2P	864973-51-3P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazacyclopenta[b]naphthalene derivs. as modulators of glucocorticoid receptor)

RN 864971-79-9 CAPLUS

CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-(phenylmethyl)- (CA INDEX NAME)



RN 864971-80-2 CAPLUS

CN 1H-Pyrazolo[3,4-g]isoquinoline, 4,4a,5,6,7,8-hexahydro-6-[[4-(4-morpholinyl)phenyl]sulfonyl]-4a-(phenylmethyl)- (CA INDEX NAME)



RN 864971-81-3 CAPLUS

CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-(phenylmethyl)- (CA INDEX NAME)



RN 864971-83-5 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(phenylmethyl)- (CA INDEX NAME)



RN 864971-84-6 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(phenylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864971-85-7 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8-hexahydro-1-(4-methoxyphenyl)-4a-(phenylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864971-86-8 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-

4,4a,5,6,7,8-hexahydro-1-(4-methylphenyl)-4a-(phenylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864971-87-9 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8-hexahydro-1,4a-bis(phenylmethyl)- (CA INDEX NAME)



RN 864971-88-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-(phenylmethyl)-1-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864971-89-1 CAPLUS
CN Benzonitrile, 4-[6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-(phenylmethyl)-1H-pyrazolo[3,4-g]isoquinolin-1-yl]- (CA INDEX NAME)



RN 864971-90-4 CAPLUS
CN Benzenesulfonamide, 4-[6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-(phenylmethyl)-1H-pyrazolo[3,4-g]isoquinolin-1-yl]- (CA INDEX NAME)



RN 864971-91-5 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8-hexahydro-1-[(3-hydroxyphenyl)methyl]-4a-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 864971-92-6 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a,6-bis(phenylmethyl)- (CA INDEX NAME)



RN 864971-93-7 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-(phenylmethyl)- (CA INDEX NAME)



RN 864971-94-8 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[(4-methoxyphenyl)methyl]-6-(phenylmethyl)- (CA INDEX NAME)



RN 864971-97-1 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8,8a,9-octahydro-4a-(phenylmethyl)-, (4aR,8aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 864971-98-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8,8a,9-octahydro-4a-(phenylmethyl)-, (4aR,8aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 864972-01-0 CAPLUS
CN 6H-Pyrazolo[3,4-g]isoquinoline-6-carboxylic acid, 1-(4-fluorophenyl)-1,4,4a,5,7,8-hexahydro-4a-methyl-, 1,1-dimethylethyl ester, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-02-1 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-03-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-6-(phenylsulfonyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-04-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-6-[(4-methylphenyl)sulfonyl]-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-05-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-6-[[4-(trifluoromethyl)phenyl]sulfonyl]-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-06-5 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-6-[[4-(4-morphol inyl)phenyl]sulfonyl]-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-07-6 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-08-7 CAPLUS
CN Benzonitrile, 4-[[(4aS)-1-(4-fluorophenyl)-1,4,4a,5,7,8-hexahydro-4a-methyl-6H-pyrazolo[3,4-g]isoquinolin-6-yl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-09-8 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-6-[(4-methoxyphenyl)sulfonyl]-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-10-1 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-11-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-6-[(2-fluorophenyl)sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-12-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-6-[(2-methylphenyl)sulfonyl]-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-13-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-6-(phenylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-14-5 CAPLUS
CN 6H-Pyrazolo[3,4-g]isoquinoline-6-sulfonamide, 1-(4-fluorophenyl)-1,4,4a,5,7,8-hexahydro-4a-methyl-N-phenyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-15-6 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[(4,4-dimethyl-1-piperidinyl)sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-16-7 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-6-(1-piperidinylsulfonyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-17-8 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-methyl-1-(4-pyridinyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-18-9 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-methyl-1-(2-pyridinyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-19-0 CAPLUS
CN Benzenamine, 4-[[(4aS)-1-(4-fluorophenyl)-1,4,4a,5,7,8-hexahydro-4a-methyl-6H-pyrazolo[3,4-g]isoquinolin-6-yl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-20-3 CAPLUS
CN 1-Propanone, 1-[(4aS)-1-(4-fluorophenyl)-1,4,4a,5,7,8-hexahydro-4a-methyl-6H-pyrazolo[3,4-g]isoquinolin-6-yl]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-23-6 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxylic acid, 1-butyl-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1,4,5,6,7,8-hexahydro-, methyl ester, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-24-7 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxylic acid, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1,4,5,6,7,8-hexahydro-1-(1-methylethyl)-, methyl ester, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-25-8 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanol, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-26-9 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanol, 1-(4-fluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-1,4,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-27-0 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanol, 1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-[(4-methylphenyl)sulfonyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-28-1 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanol, 1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-(phenylsulfonyl)-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-29-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(methoxymethyl)-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-30-5 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[(2-methoxyethoxy)methyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-31-6 CAPLUS
CN Ethanol, 2-[[(4aR)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-(phenylsulfonyl)-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-32-7 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4a-(ethoxymethyl)-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-33-8 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[(3-methoxypropoxy)methyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-34-9 CAPLUS
CN Propanenitrile, 3-[[(4aR)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-35-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[[2-(4-morpholinyl)ethoxy]methyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-36-1 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[[2-(1-piperidinyl)ethoxy]methyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-37-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-

1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[[2-(1-pyrrolidinyl)ethoxy]methyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-38-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-[(2-methoxyethoxy)methyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-39-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-(methoxymethyl)-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-40-7 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(methoxymethyl)-6-[(4-methylphenyl)sulfonyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-41-8 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[(2-methoxyethoxy)methyl]-6-[(4-methylphenyl)sulfonyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-42-9 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[(2-methoxyethoxy)methyl]-6-(phenylsulfonyl)-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-43-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(methoxymethyl)-6-(phenylsulfonyl)-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-44-1 CAPLUS
CN 6H-Pyrazolo[3,4-g]isoquinoline-6-sulfonamide,
1-(4-fluorophenyl)-1,4,4a,5,7,8-hexahydro-4a-[(2-methoxyethoxy)methyl]-N,N-dimethyl-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-45-2 CAPLUS
CN 6H-Pyrazolo[3,4-g]isoquinoline-6-sulfonamide,
1-(4-fluorophenyl)-1,4,4a,5,7,8-hexahydro-4a-(methoxymethyl)-N,N-dimethyl-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-46-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-(butylsulfonyl)-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[(2-methoxyethoxy)methyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-47-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-[(2-methoxyethoxy)methyl]-1-methyl-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-48-5 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-butyl-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-[(2-methoxyethoxy)methyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-49-6 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-[(2-methoxyethoxy)methyl]-1-(1-methylethyl)-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-50-9 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-(methoxymethyl)-1-(1-methylethyl)-, (4aR)- (CA

INDEX NAME)

Absolute stereochemistry.



RN 864972-51-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-butyl-4,4a,5,6,7,8-hexahydro-4a-(methoxymethyl)-6-[(4-methylphenyl)sulfonyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-52-1 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-butyl-4,4a,5,6,7,8-hexahydro-4a-[(2-methoxyethoxy)methyl]-6-[(4-methylphenyl)sulfonyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-54-3 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-N,N-dimethyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-55-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(4-morpholinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-56-5 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(4-morpholinylmethyl)-6-[[4-(trifluoromethyl)phenyl]sulfonyl]-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-57-6 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[(cyclopropylmethyl)sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(4-morpholinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-58-7 CAPLUS

CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(1-pyrrolidinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-59-8 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-N-ethyl-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-60-1 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-N,N-diethyl-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-61-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(1-piperidinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-62-3 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-N-(2-methoxyethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-63-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[(4-methyl-1-piperazinyl)methyl]-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-64-5 CAPLUS
CN 1,2-Ethanediamine, N2-[[(4aS)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]methyl]-N1,N1-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-65-6 CAPLUS
CN 1,2-Ethanediamine, N1-[[(4aS)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]methyl]-N1,N2,N2-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-66-7 CAPLUS
CN 1,3-Propanediamine, N3-[[(4aS)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]methyl]-N1,N1-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-67-8 CAPLUS
CN 1,3-Propanediamine, N1-[[(4aS)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]methyl]-N1,N3,N3-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-68-9 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-N-(2-methoxyethyl)-N-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-69-0 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-N-(1-methylethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-70-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 4a-(1-azetidinylmethyl)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-71-4 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-N-2-propen-1-yl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-72-5 CAPLUS
CN Ethanol, 2-[[[(4aS)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]methyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-73-6 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-N,N-dimethyl-6-[(4-methylphenyl)sulfonyl]-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-74-7 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-6-[(4-methylphenyl)sulfonyl]-4a-(1-pyrrolidinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-75-8 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 1-(4-fluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-1,4,5,6,7,8-hexahydro-N,N-dimethyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-76-9 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-(1-pyrrolidinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-77-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-6-(phenylsulfonyl)-4a-(1-pyrrolidinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-78-1 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-N,N-dimethyl-6-(phenylsulfonyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-79-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(4-morpholinylmethyl)-6-(phenylsulfonyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-80-5 CAPLUS
CN Ethanol, 2-[[[(4aS)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]methyl]methylamino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-81-6 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-(butylsulfonyl)-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(4-morpholinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-82-7 CAPLUS
CN Benzonitrile, 4-[[(4aS)-1-(4-fluorophenyl)-1,4,4a,5,7,8-hexahydro-4a-(4-morpholinylmethyl)-6H-pyrazolo[3,4-g]isoquinolin-6-yl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-83-8 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, N,N-diethyl-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-(phenylsulfonyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-84-9 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, N,N-diethyl-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-[(4-methoxyphenyl)sulfonyl]-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-85-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-6-(phenylsulfonyl)-4a-(1-piperidinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-86-1 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-6-[(4-methoxyphenyl)sulfonyl]-4a-(1-piperidinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-87-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-butyl-4,4a,5,6,7,8-hexahydro-6-[(4-methylphenyl)sulfonyl]-4a-(1-piperidinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-88-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-(1-pyrrolidinylmethyl)-1-(2,2,2-trifluoroethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-89-4 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 1-butyl-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1,4,5,6,7,8-hexahydro-N,N-dimethyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-90-7 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-butyl-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-(1-piperidinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-91-8 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanamine, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1,4,5,6,7,8-hexahydro-N,N-dimethyl-1-(1-methylethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-92-9 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-

4,4a,5,6,7,8-hexahydro-1-(1-methylethyl)-4a-(1-piperidinylmethyl)-, (4aS)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 864972-93-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-6-[(2-methylphenyl)sulfonyl]-4a-(4-morpholinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-94-1 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-6-[(2-fluorophenyl)sulfonyl]-4,4a,5,6,7,8-hexahydro-4a-(4-morpholinylmethyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-95-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(4-morpholinylmethyl)-6-(2-pyridinylsulfonyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-97-4 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxylic acid,
6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-
1,4,5,6,7,8,8a,9-octahydro-, methyl ester, (4aR,8aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864972-99-6 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-
1-(4-fluorophenyl)-4,4a,5,6,7,8,8a,9-octahydro-4a-(methoxymethyl)-,
(4aR,8aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-00-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-
1-(4-fluorophenyl)-4,4a,5,6,7,8,8a,9-octahydro-4a-[(2-
methoxyethoxy)methyl]-, (4aR,8aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-01-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8,8a,9-octahydro-4a-[(2-methoxyethoxy)methyl]-6-(phenylsulfonyl)-, (4aR,8aS)-(CA INDEX NAME)

Absolute stereochemistry.



RN 864973-02-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8,8a,9-octahydro-4a-(methoxymethyl)-6-(phenylsulfonyl)-, (4aR,8aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-04-6 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxamide, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-N-(phenylmethyl)-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-05-7 CAPLUS
CN Methanone, [(4aR)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]-4-morpholinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-06-8 CAPLUS
CN Methanone, [(4aR)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]-1-piperidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-08-0 CAPLUS
CN Methanone, [(4aR)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]-1-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-09-1 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxamide,
6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-N-ethyl-1-(4-fluorophenyl)-
1,4,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-11-5 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxamide,
6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-
hexahydro-N,N-dimethyl-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-12-6 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanol,
6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-
hexahydro-α-methyl-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-13-7 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanol, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-α-ethyl-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-14-8 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanol, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-α-phenyl-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-15-9 CAPLUS
CN Methanone, [(4aR)-6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl]phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-16-0 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxylic acid, 1-butyl-1,4,5,6,7,8-hexahydro-6-[(4-methylphenyl)sulfonyl]-, methyl ester, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-17-1 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-cyclopentyl-4,4a,5,6,7,8-hexahydro-4a-[(2-methoxyethoxy)methyl]-6-[(4-methylphenyl)sulfonyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-23-9 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-ethanamine, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-N,N-dimethyl-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-24-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-[2-(1-pyrrolidinyl)ethyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-25-1 CAPLUS
CN 6H-Pyrazolo[3,4-g]isoquinoline-6-carboxylic acid, 1-(4-fluorophenyl)-1,4,4a,5,7,8,8a,9-octahydro-4a-(4-morpholinylmethyl)-, 1,1-dimethylethyl ester, (4aS,8aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-26-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8,8a,9-octahydro-4a-(4-morpholinylmethyl)-, (4aS,8aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864973-27-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro- (CA INDEX NAME)



RN 864973-28-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-(phenylsulfonyl)- (CA INDEX NAME)



RN 864973-29-5 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



RN 864973-30-8 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-

fluorophenyl)methyl]-6-[(4-fluorophenyl)sulfonyl]-4,4a,5,6,7,8-hexahydro- (CA INDEX NAME)



RN 864973-31-9 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-(methylsulfonyl)- (CA INDEX NAME)



RN 864973-32-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-(butylsulfonyl)-1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro- (CA INDEX NAME)



RN 864973-33-1 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-6-[(1-methylethyl)sulfonyl]-4a-(phenylmethyl)- (CA INDEX NAME)



RN 864973-34-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-[(1-methyl-1H-imidazol-4-yl)sulfonyl]- (CA INDEX NAME)



RN 864973-35-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)sulfonyl]-1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro- (CA INDEX NAME)



RN 864973-36-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[6-(1,1-dimethylethyl)-3-pyridinyl]sulfonyl]-1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro- (CA INDEX NAME)



RN 864973-37-5 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-[[4-(4-morpholinyl)phenyl]sulfonyl]- (CA INDEX NAME)



RN 864973-38-6 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 864973-39-7 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 864973-40-0 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 864973-41-1 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[6-(1,1-dimethylethyl)-3-pyridinyl]methyl]-1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro- (CA INDEX NAME)



RN 864973-42-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-propyl- (CA INDEX NAME)



RN 864973-43-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-6-(1H-imidazol-5-ylmethyl)-4a-(phenylmethyl)- (CA INDEX NAME)



RN 864973-44-4 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-(phenylmethyl)-6-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 864973-45-5 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-phenyl- (CA INDEX NAME)



RN 864973-46-6 CAPLUS
CN 6H-Pyrazolo[3,4-g]isoquinoline-6-carboxamide, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-1,4,4a,5,7,8-hexahydro-N-

phenyl- (CA INDEX NAME)



RN 864973-47-7 CAPLUS
CN 6H-Pyrazolo[3,4-g]isoquinoline-6-sulfonamide,
1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-1,4,4a,5,7,8-hexahydro-N-
phenyl- (CA INDEX NAME)



RN 864973-48-8 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-
fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-(4-morpholinylsulfonyl)-
(CA INDEX NAME)



RN 864973-49-9 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-
fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-[(4-methyl-1-
piperazinyl)sulfonyl]- (CA INDEX NAME)



RN 864973-50-2 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 1-(4-fluorophenyl)-4a-[(4-fluorophenyl)methyl]-4,4a,5,6,7,8-hexahydro-6-(1-piperidinylsulfonyl)- (CA INDEX NAME)



RN 864973-51-3 CAPLUS
CN 6H-Pyrazolo[3,4-g]isoquinoline-6-acetamide, 1-(4-fluorophenyl)-1,4,4a,5,7,8-hexahydro-N,N-dimethyl-4a-(phenylmethyl)- (CA INDEX NAME)



IT 1037050-35-3 1037050-69-3 1037168-91-4
1037183-57-5 1037184-08-9 1037192-71-4
1037201-81-2 1037204-60-6 1037208-30-2
1037210-83-5 1037212-67-1 1037215-77-2
1037217-31-4 1037219-07-0 1037220-44-2
1037221-90-1 1037222-68-6 1037239-93-2
1037292-19-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of triazacyclopenta[b]naphthalene derivs. as modulators of glucocorticoid receptor)

RN 1037050-35-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 4,4a,5,6,7,8-hexahydro-4a-methyl-1-(4-pyridinyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1037050-69-3 CAPLUS
CN 1H-Pyrazolo[3,4-g]isoquinoline, 4,4a,5,6,7,8-hexahydro-4a-methyl-1-(2-pyridinyl)-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1037168-91-4 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxylic acid, 1-(4-fluorophenyl)-6-[(4-fluorophenyl)sulfonyl]-1,4,5,6,7,8-hexahydro-, methyl ester, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1037183-57-5 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxylic acid, 1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-[(4-methylphenyl)sulfonyl]-, methyl ester, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1037184-08-9 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxylic acid, 1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-(phenylsulfonyl)-, methyl ester, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1037192-71-4 CAPLUS
CN 6H-Pyrazolo[3,4-g]isoquinoline-6-sulfonamide, 1-(4-fluorophenyl)-1,4,4a,5,7,8-hexahydro-4a-(hydroxymethyl)-N,N-dimethyl-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1037201-81-2 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanol, 6-(butylsulfonyl)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1037204-60-6 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-methanol,
6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1,4,5,6,7,8-hexahydro-1-methyl-,
(4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1037208-30-2 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxaldehyde,
1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-6-[[4-
(trifluoromethyl)phenyl]sulfonyl]-, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1037210-83-5 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxaldehyde,
6-[(cyclopropylmethyl)sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-,
(4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1037212-67-1 CAPLUS
CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxaldehyde, 6-(butylsulfonyl)-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1037215-77-2 CAPLUS
CN Benzonitrile, 4-[[(4aS)-1-(4-fluorophenyl)-4a-formyl-1,4,4a,5,7,8-hexahydro-6H-pyrazolo[3,4-g]isoquinolin-6-yl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

<------User Break------>

=> d abs fbib fhitstr 7-9

L7 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
AB Three-dimensional quant. structure-activity relationship (3D-QSAR) models were constructed using comparative mol. field anal. (Co-MFA) on a series of opioid receptor antagonists. To obtain statistically significant and robust Co-MFA models, a sizable data set of naltrindole and naltrexone analogs was assembled by pooling biol. and structural data from independent studies. A process of "leave one data set out", similar to the traditional "leave one out" cross-validation procedure employed in partial least squares (PLS) anal., was utilized to study the feasibility of pooling data in the present case. These studies indicate that our approach yields statistically significant and highly predictive Co-MFA models from the pooled data set of δ, μ, and κ opioid receptor antagonists. All models showed excellent internal predictability and self-consistency: q2 = 0.69/r2 = 0.91 (δ), q2 = 0.67/r2 = 0.92 (μ), and q2 = 0.60/r2 = 0.96 (κ). The Co-MFA models were further validated using two sep. test sets: one test set was selected randomly from the pooled data set, while the other test set was retrieved from other published sources. The overall excellent agreement between Co-MFA-predicted and exptl. binding affinities for a structurally diverse array of ligands across all three opioid receptor subtypes gives testimony to the superb predictive power of these models. Co-MFA field anal. demonstrated that the variations in binding affinity of opioid antagonists are dominated by steric rather than electrostatic interactions with the three opioid receptor binding sites. The Co-MFA steric-electrostatic contour maps corresponding to the δ, μ, and κ opioid receptor subtypes reflected the characteristic similarities and differences in the familiar "message-address" concept of opioid receptor ligands. Structural modifications to increase selectivity for the δ over μ and κ opioid receptors have been predicted on the basis of the Co-MFA contour maps. The structure-activity relationships (SARs) together with the Co-MFA models should find utility for the rational design of subtype-selective opioid receptor antagonists.
AN 2005:127600 CAPLUS Full-text

DN 142:348119
TI 3D-QSAR Comparative Molecular Field Analysis on Opioid Receptor Antagonists: Pooling Data from Different Studies
AU Peng, Youyi; Keenan, Susan M.; Zhang, Qiang; Kholodovych, Vladyslav; Welsh, William J.
CS Department of Pharmacology and the Informatics Institute of UMDNJ, University of Medicine Dentistry of New Jersey-Robert Wood Johnson Medical School (UMDNJ-RWJMS), Piscataway, NJ, 08854, USA
SO Journal of Medicinal Chemistry (2005), 48(5), 1620-1629
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
IT 384820-59-1
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(3D-QSAR comparative mol. field anal. on opioid receptor antagonists using data from different studies)
RN 384820-59-1 CAPLUS
CN 5,10c-(Iminoethano)-10cH-furo[2',3',4',5':4,5]phenanthro[3,2-c]pyrazol-5a(6H)-ol, 4,5,9,9b-tetrahydro-1-methoxy-13-(2-methyl-2-propenyl)-, (5R,5aS,9bR,10cS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
AB Data on opioid abuse liability evaluations of compds. using rhesus monkeys are presented. These data usually involve in vitro evaluation in opioid binding assays, and the compds. may be evaluated for discriminative and reinforcing effects.
AN 2003:745070 CAPLUS Full-text
DN 140:264237
TI Evaluation of new compounds for opioid activity (2002)
AU Woods, J. H.; Ko, M.-C.; Winger, G.; France, C. P.; Traynor, J. R.
CS Departments of Pharmacology and Psychology, University of Michigan, Ann Arbor, MI, USA
SO NIDA Research Monograph (2003), 183(Problems of Drug Dependence 2002), 170-190
CODEN: MIDAD4; ISSN: 0361-8595
PB National Institute on Drug Abuse
DT Journal

LA English
IT 674347-15-0
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(evaluation of new compds. for opioid activity)
RN 674347-15-0 CAPLUS
CN 5,10c-(Iminoethano)-10cH-furo[2',3',4',5':4,5]phenanthro[3,2-c]pyrazole-1,5a(6H)-diol, 4,5,9,9b-tetrahydro-9,13-dimethyl-, dihydrochloride, (5R,5aS,9bR,10cS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2010 ACS on STN
AB The results of a five-year (1997-2002) analgesic and stimulant/depressant testing program, conducted by the Drug Evaluation Committee of the College on Problems of Drug Dependence, are presented. The names of the compds. evaluated, and their mol. structures and a summary of their in vivo and in vitro data are also included.
AN 2003:745069 CAPLUS Full-text
DN 140:264236
TI Biological evaluation of compounds for their physical dependence potential and abuse liability. XXVI. Drug Evaluation Committee of the College on Problems of Drug Dependence (2002)
AU Coop, A.
CS Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA
SO NIDA Research Monograph (2003), 183(Problems of Drug Dependence 2002), 152-169
CODEN: MIDAD4; ISSN: 0361-8595
PB National Institute on Drug Abuse
DT Journal
LA English
IT 674347-15-0
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(biol. evaluation of compds. for their phys. dependence potential and abuse liability)
RN 674347-15-0 CAPLUS
CN 5,10c-(Iminoethano)-10cH-furo[2',3',4',5':4,5]phenanthro[3,2-c]pyrazole-

1,5a(6H)-diol, 4,5,9,9b-tetrahydro-9,13-dimethyl-, dihydrochloride, (5R,5aS,9bR,10cS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	84.84	293.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.90	-15.30

FILE 'STNGUIDE' ENTERED AT 16:07:10 ON 28 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 23, 2010 (20100423/UP).

=> logoff y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.14	293.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-15.30

STN INTERNATIONAL LOGOFF AT 16:08:08 ON 28 APR 2010

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS 3	JAN 25	Annual Reload of MEDLINE database
NEWS 4	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS 5	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS 6	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS 7	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS 8	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses
NEWS 9	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS 10	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS 11	APR 02	DWPI: New display format ALLSTR available
NEWS 12	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS 13	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS 14	APR 07	CA/CAplus CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields
NEWS 15	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAplus
NEWS 16	APR 07	MEDLINE Coverage Is Extended Back to 1947
NEWS 17	JUN 16	WPI First View (File WPIFV) will no longer be available after July 30, 2010
NEWS 18	JUN 18	DWPI: New coverage - French Granted Patents
NEWS 19	JUN 18	CAS and FIZ Karlsruhe announce plans for a new STN platform
NEWS 20	JUN 18	IPC codes have been added to the INSPEC backfile (1969-2009)
NEWS 21	JUN 21	Removal of Pre-IPC 8 data fields streamline displays in CA/CAplus, CASREACT,and MARPAT
NEWS 22	JUN 21	Access an additional 1.8 million records exclusively enhanced with 1.9 million CAS Registry Numbers -- EMBASE Classic on STN
NEWS 23	JUN 28	Introducing "CAS Chemistry Research Report": 40 Years of Biofuel Research Reveal China Now Atop U.S. in Patenting and Commercialization of Bioethanol
NEWS 24	JUN 29	Enhanced Batch Search Options in DGENE, USGENE, and PCTGEN

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2, AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:06:10 ON 14 JUL 2010

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 16:06:30 ON 14 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JUL 2010 HIGHEST RN 1231819-66-1
DICTIONARY FILE UPDATES: 13 JUL 2010 HIGHEST RN 1231819-66-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10591884.str






chain nodes :
14
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 15 16 17 18 19 20 21 22 23 24
25 26
chain bonds :
7-14
ring bonds :
1-2 1-5 1-9 2-3 3-4 4-5 5-6 6-7 7-8 7-10 8-9 8-13 10-11 11-12 12-13
15-16 15-20 16-17 17-18 18-19 19-20 21-22 21-26 22-23 23-24 24-25 25-26
exact/norm bonds :
1-2 1-5 1-9 2-3 3-4 4-5 5-6 6-7 7-8 7-10 7-14 8-9 8-13 10-11 11-12
12-13 15-16 15-20 16-17 17-18 18-19 19-20
normalized bonds :
21-22 21-26 22-23 23-24 24-25 25-26

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS
26:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:06:49 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 173 TO ITERATE

100.0% PROCESSED 173 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2671 TO 4249
PROJECTED ANSWERS: 8 TO 329

L2 8 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 16:06:54 FILE 'REGISTRY'

FILE COVERS 1907 - 14 Jul 2010 VOL 153 ISS 3
FILE LAST UPDATED: 13 Jul 2010 (20100713/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4 2 L3

=> d abs bib fhitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN

AB Addn. of the 4-fluorophenylpyrazole group to the previously described 2-azadecalin glucocorticoid receptor (GR) antagonist 1 resulted in significantly enhanced functional activity. SAR of the bridgehead substituent indicated that whereas groups as small as Me afforded high GR binding, GR functional activity was enhanced by larger groups such as benzyl, substituted ethers, and aminoalkyl derivs. GR antagonists with binding and functional activity comparable to mifepristone were discovered (e.g., 52: GR binding Ki 0.7 nM; GR reporter gene functional Ki 0.6 nM) and found to be highly selective over other steroid receptors. Analogs 43 and 45 had >50% oral bioavailability in the dog.

AN 2008:232071 CAPLUS Full-text
DN 148:440269

TI 1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity

AU Clark, Robin D.; Ray, Nicholas C.; Williams, Karen; Blaney, Paul; Ward, Stuart; Crackett, Peter H.; Hurley, Christopher; Dyke, Hazel J.; Clark, David E.; Lockey, Peter; Devos, Rene; Wong, Melanie; Porres, Soraya S.; Bright, Colin P.; Jenkins, Robert E.; Belanoff, Joseph
CS Corcept Therapeutics, Menlo Park, CA, 94025, USA

SO Bioorganic & Medicinal Chemistry Letters (2008), 18(4), 1312-1317
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 148:440269

IT 864972-02-1P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(1H-pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists)

RN 864972-02-1 CAPLUS

CN 1H-Pyrazolo[3,4-g]isoquinoline, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-4,4a,5,6,7,8-hexahydro-4a-methyl-, (4aS)- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I



II

AB Title compds. I [L1 and L2 independently = a bond, O, S, etc.; A = (un)substituted 5-6 membered heterocycloalkyl or heteroaryl; R1 = H, (un)substituted alkyl, heteroalkyl, etc.; R2 = (un)substituted alkyl, heteroalkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of glucocorticoid receptor. Thus, II was prepared by cyclization of (S)-8a-benzyl-2-(4-tert-butyl-benzenesulfonyl)-7-(1-hydroxy-meth-(Z)- ylidene]-1,3,4,7,8,8a-hexahydro-2H-isoquinolin-6-one (preparation given) with hydrazine hydrate. The activity of I was evaluated in glucocorticoid receptor binding assay and it was revealed that selected compds. of the invention displayed IC50 values in the range of 10 up to 100 nm and others below 10 nM. Pharmaceutical compns. comprising I are disclosed.

AN 2005:1021750 CAPLUS Full-text

DN 143:306309

TI Preparation of triazacyclopenta[b]naphthalene derivatives as modulators of glucocorticoid receptor

IN Clark, Robin D.; Ray, Nicholas C.; Blaney, Paul M.; Hurley, Christopher A.; Williams, Karen

PA Corcept Therapeutics, Inc., USA

SO PCT Int. Appl., 160 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005087769	A1	20050922	WO 2005-US8049	20050309
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005222421	A1	20050922	AU 2005-222421	20050309

	CA 2558899	A1	20050922	CA 2005-2558899	20050309
	EP 1735308	A1	20061227	EP 2005-725295	20050309
	EP 1735308	B1	20080910		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 101027301	A	20070829	CN 2005-80011481	20050309
	JP 2007528417	T	20071011	JP 2007-503030	20050309
	AT 407934	T	20080915	AT 2005-725295	20050309
	PT 1735308	E	20081202	PT 2005-725295	20050309
	ES 2313317	T3	20090301	ES 2005-725295	20050309
	ZA 2006008306	A	20090225	ZA 2006-8306	20061005
	KR 2007029684	A	20070314	KR 2006-720988	20061009
	IN 2006CN03745	A	20070615	IN 2006-CN3745	20061009
	US 20070281928	A1	20071206	US 2007-591884	20070507
	HK 1104813	A1	20090403	HK 2007-106903	20070627
PRAI	US 2004-551836P	P	20040309		
	WO 2005-US8049	W	20050309		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 143:306309; MARPAT 143:306309

IT 864972-22-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of triazacyclopenta[b]naphthalene derivs. as modulators of glucocorticoid receptor)

RN 864972-22-5 CAPLUS

CN 4aH-Pyrazolo[3,4-g]isoquinoline-4a-carboxylic acid, 6-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-, methyl ester, (4aR)- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file registry
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10591884.str



chain nodes :
14
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13
chain bonds :
7-14
ring bonds :
1-2 1-5 1-9 2-3 3-4 4-5 5-6 6-7 7-8 7-10 8-9 8-13 10-11 11-12 12-13
exact/norm bonds :
1-2 1-5 1-9 2-3 3-4 4-5 5-6 6-7 7-8 7-10 8-9 8-13 10-11 11-12 12-13
exact bonds :
7-14

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS

L5 STRUCTURE UPLOADED

=> d 15
L5 HAS NO ANSWERS
L5 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l5
SAMPLE SEARCH INITIATED 16:09:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      474 TO ITERATE

100.0% PROCESSED      474 ITERATIONS                              10 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         8174 TO    10786
PROJECTED ANSWERS:              11 TO      389

L6           10 SEA SSS SAM L5

=> s l5 full
FULL SEARCH INITIATED 16:09:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    10016 TO ITERATE

100.0% PROCESSED    10016 ITERATIONS                            200 ANSWERS
SEARCH TIME: 00.00.01

L7          200 SEA SSS FUL L5

=> file caplus
http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l7
L8            2 L7

=> d his

     (FILE 'HOME' ENTERED AT 16:06:10 ON 14 JUL 2010)

     FILE 'REGISTRY' ENTERED AT 16:06:30 ON 14 JUL 2010
L1               STRUCTURE UPLOADED
L2             8 S L1
L3           163 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 16:06:58 ON 14 JUL 2010
L4             2 S L3

     FILE 'REGISTRY' ENTERED AT 16:09:03 ON 14 JUL 2010
L5               STRUCTURE UPLOADED
L6            10 S L5
L7           200 S L5 FULL

     FILE 'CAPLUS' ENTERED AT 16:09:38 ON 14 JUL 2010
L8             2 S L7

=> s l8 not l4
L9             0 L8 NOT L4

=> file stnguide
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul  9, 2010 (20100709/UP).
```